Gynecology Drugs Market

Gynecology Drugs Market (Therapeutics: Hormonal Therapy and Non-hormonal Therapy; Indication: Gynecological Cancers, Endometriosis, Female Infertility, Menopausal Disorder, Gynecology Infections, Polycystic Ovary Syndrome, and Contraception) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Gynecology Drugs Market Outlook 2031

  • The global industry was valued at US$ 63.4 Bn in 2022
  • It is expected to grow at a CAGR of 4.8% from 2023 to 2031 and reach US$ 96.1 Bn by the end of 2031

Analyst Viewpoint

Increase in incidence of gynecological disorders is driving the gynecology drugs market size. Gynecology drugs treat cancers of the reproductive system, cramping, pre-menstrual syndrome, and menstrual disorders such as menorrhagia.

Rise in awareness about the advantages of non-hormonal therapy is translating into extensive research being conducted in the gynecology drugs market scenario.

Manufacturers are exploring the incorporation of intrauterine devices that can exercise effective control over postpartum hemorrhage.

They are also looking toward the production of PARP inhibitors, which have been approved by the U.S. Food and Drug Administration for the treatment of gynecological cancers.

Market Introduction

Gynecology drugs, also known as reproductive health drugs, imply medications for illnesses that affect the reproductive system, thereby enclosing care for women during as well as after pregnancy. Such drugs treat numerous gynecological diseases that are likely to impact ovaries, uterus, and appendages.

Primary therapeutic categories are inclusive of non-hormonal and hormonal therapy. Hormonal therapy implies treatments adding, blocking, or removing hormones to impede the growth of cancer cells, whereas non-hormonal therapy involves the usage of anti-inflammatory and anti-infective agents, moisturizers, lubricants, and antidepressants.

Apart from treating gynecological cancers, gynecology drugs act as menstrual disorders medications, hormonal gynecological treatments, fertility-enhancing pharmaceuticals, and pregnancy-related medications as well.

However, high cost of hormonal therapies is expected to restrain the gynecology drugs market growth during the forecast period. As per the National Institutes of Health, the lifetime price of hormone therapy with tamoxifen, AI, and switch therapy was US$ 17,759, US$ 15,766, and US$ 15,464, respectively in 2021.

Attribute Detail
Market Drivers
  • Growth in Incidence of Gynecological Diseases
  • Rise in Awareness Regarding Gynecological Wellbeing

Growth in Incidence of Gynecological Diseases Fueling Gynecology Drugs Market Demand

Common symptoms of gynecological diseases include strange vaginal dying, vaginal release, vaginal tingling, pelvic agony, and bosom torment and protuberances.

If left untreated, these diseases may culminate into abnormal vaginal bleeding, burning sensation during urination, bleeding post-menopause, lumps or sores in the genital area, and increased vaginal discharge.

Developing economies are witnessing a higher percentage of women at risk of these ailments as compared to the developed economies, as menstrual hygiene is still a taboo topic in these countries.

Reluctance to discuss these problems openly forces these women to bear the torture solitarily, thereby resulting in the above-mentioned aftereffects. Awareness campaigns are expected to provide respite to the women suffering from these symptoms.

According to the World Health Organization, over 570,000 women worldwide suffer from cervical cancer with 311,000 women succumbing to it.

However, healthcare personnel state that cervical cancer is a successfully treatable form of cancer, only if it is diagnosed early and managed effectively. Gynecology drugs, if timely administered, can help in reducing these deaths. It also states that 9% of women worldwide contract endometrial cancer.

Surge in prevalence of polycystic ovary syndrome is driving the gynecology drugs market revenue. As per an article published in August 2022 by Cureus, polycystic ovary syndrome (PCOS) was found in 6.8% of the participants in clinical trials.

Rise in Awareness Regarding Gynecological Wellbeing Boosting Market Progress

Out of ovarian, uterine/endometrial, cervical, vulvar, and vaginal cancers, screenings are available only for cervical cancer as of now. Gynecological cancer awareness campaigns are organized worldwide in line with gynecological cancer awareness month observed every September.

The objective is to bring professionals as well as health consumers together to conduct awareness campaigns pertaining to sexual/gynecological health. Thus, increase in awareness regarding gynecological well-being is augmenting the gynecology drugs market development.

Awareness campaigns apprise about the importance of conduction of transvaginal ultrasound or routine sonography, pap smear test for cervical cancer, colposcopy, cystoscopy, curettage, hysteroscopy, and ultimately check for sexually transmitted diseases (STDs) such as chlamydia, gonorrhea, HIV, and syphilis.

Regional Outlook

Attribute Detail
Leading Region North America

According to the latest gynecology drugs market trends, North America held largest share in 2022. Rise in incidences of breast cancer, polycystic ovary syndrome, and menopausal disorders amongst women in the U.S. and Canada is fueling the market dynamics of the region.

According to the report shared by the Canadian Cancer Society in May 2022, close to 1,450 women in Canada were diagnosed with cervical cancer in 2022. Furthermore, as per the American Cancer Society’s report published in January 2022, breast cancer affects 30% of the women in the U.S.

According to the latest gynecology drugs market forecast, the industry in Asia Pacific is expected to grow at a steady pace in the near future. Rise in awareness regarding health and well-being is boosting the demand for advanced gynecological treatments, thereby driving the gynecology drugs industry share in Asia Pacific.

Analysis of Key Players in Gynecology Drugs Market

Key players in the global gynecology drugs industry are engaging in conducting clinical trials regarding non-hormonal therapy to treat gynecological disorders.

For instance, Bayer, in October 2021, started with a Phase III clinical development program called OASIS to evaluate the safety and efficacy of elinzanetant to treat vasomotor symptoms while battling menopause.

Allergan plc, Amgen Inc., Bayer AG, Merck & Co., Inc., Pfizer Inc., Eli Lilly Company, F. Hoffmann-La Roche Ltd., and AstraZeneca are key players in the market.

These companies have been profiled in the gynecology drugs market report based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.

Key Developments in Gynecology Drugs Market

  • In February 2023, GSK plc announced that the U.S. FDA had granted 100% approval for Jemperli to treat adults suffering from mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer
  • In September 2022, Lynparza obtained approval in China as the very first line of treatment regarding administration of bevacizumab for homologous recombination deficiency (HRD)-positive advanced ovarian cancer

Gynecology Drugs Market Snapshot

Attribute Detail
Market Size in 2022 US$ 63.4 Bn
Market Forecast (Value) in 2031 US$ 96.1 Bn
Growth Rate (CAGR) 4.8%
Forecast Period 2023-2031
Historical Data Available for 2017-2021
Quantitative Units US$ Bn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Therapeutics
    • Hormonal Therapy (Estrogen Therapy, Progestin Therapy, Combination Therapy, Thyroid Replacement Therapy, Parathyroid Hormone Therapy, and Others)
    • Non-hormonal Therapy (Anti-Infective Agents, Anti-neoplastic Agents, Anti-inflammatory Agents, and Others)
  • Indication
    • Gynecological Cancers
    • Endometriosis
    • Female Infertility
    • Menopausal Disorder
    • Gynecology Infections
    • Polycystic Ovary Syndrome
    • Contraception (Birth Control)
    • Others
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC
Companies Profiled
  • Allergan plc
  • Amgen Inc.
  • Bayer AG
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Eli Lilly Company
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca
Customization Scope Available Upon Request
Pricing Available Upon Request

Frequently Asked Questions

How big was the global gynecology drugs market in 2022?

It was valued at US$ 63.4 Bn in 2022

How is gynecology drugs business expected to grow during the forecast period?

It is projected to grow at a CAGR of 4.8% from 2023 to 2031

What are the key factors driving the demand for gynecology drugs?

Growth in incidence of gynecological diseases and rise in awareness regarding gynecological wellbeing

Which gynecology drugs distribution channel held the largest share in 2022?

Hospital pharmacies accounted for the largest share in 2022

Which region dominated the global gynecology drugs landscape in 2022?

North America was the dominant region in gynecology drugs market in 2022

Who are the key gynecology drug manufacturers?

Allergan plc, Amgen Inc., Bayer AG, Merck & Co., Inc., Pfizer Inc., Eli Lilly Company, F. Hoffmann-La Roche Ltd., and AstraZeneca

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Gynecology Drugs Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Product Definition

            4.1.2. Industry Evolution/Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Gynecology Drugs Market Analysis and Forecast, 2017-2031

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. Key Product/Brand Analysis

        5.3. Key Mergers & Acquisitions

        5.4. COVID-19 Pandemic Impact on Industry

    6. Global Gynecology Drugs Market Analysis and Forecast, by Therapeutics

        6.1. Introduction & Definition

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Therapeutics, 2017-2031

            6.3.1. Hormonal Therapy

                6.3.1.1. Estrogen Therapy

                6.3.1.2. Progestin Therapy

                6.3.1.3. Combination Therapy

                6.3.1.4. Thyroid Replacement Therapy

                6.3.1.5. Parathyroid Hormone Therapy

                6.3.1.6. Others

            6.3.2. Non-hormonal Therapy

                6.3.2.1. Anti-Infective Agents

                6.3.2.2. Anti-neoplastic Agents

                6.3.2.3. Anti-inflammatory Agents

                6.3.2.4. Others

        6.4. Market Attractiveness Analysis, by Therapeutics

    7. Global Gynecology Drugs Market Analysis and Forecast, by Indication

        7.1. Introduction & Definition

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Indication, 2017-2031

            7.3.1. Gynecological Cancers

            7.3.2. Endometriosis

            7.3.3. Female Infertility

            7.3.4. Menopausal Disorder

            7.3.5. Gynecology Infections

            7.3.6. Polycystic Ovary Syndrome

            7.3.7. Contraception (Birth Control)

            7.3.8. Others

        7.4. Market Attractiveness Analysis, by Indication

    8. Global Gynecology Drugs Market Analysis and Forecast, by Distribution Channel

        8.1. Introduction & Definition

        8.2. Key Findings/Developments

        8.3. Market Value Forecast, by Distribution Channel, 2017-2031

            8.3.1. Hospital Pharmacies

            8.3.2. Retail Pharmacies

            8.3.3. Online Pharmacies

        8.4. Market Attractiveness Analysis, by Indication

    9. Global Gynecology Drugs Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region, 2017-2031

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness Analysis, by Region

    10. North America Gynecology Drugs Market Analysis and Forecast

        10.1. Introduction

        10.2. Key Findings

        10.3. Market Value Forecast, by Therapeutics, 2017-2031

            10.3.1. Hormonal Therapy

                10.3.1.1. Estrogen Therapy

                10.3.1.2. Progestin Therapy

                10.3.1.3. Combination Therapy

                10.3.1.4. Thyroid Replacement Therapy

                10.3.1.5. Parathyroid Hormone Therapy

                10.3.1.6. Others

            10.3.2. Non-hormonal Therapy

                10.3.2.1. Anti-Infective Agents

                10.3.2.2. Anti-neoplastic Agents

                10.3.2.3. Anti-inflammatory Agents

                10.3.2.4. Others

        10.4. Market Value Forecast, by Indication, 2017-2031

            10.4.1. Gynecological Cancers

            10.4.2. Endometriosis

            10.4.3. Female Infertility

            10.4.4. Menopausal Disorder

            10.4.5. Gynecology Infections

            10.4.6. Polycystic Ovary Syndrome

            10.4.7. Contraception (Birth Control)

            10.4.8. Others

        10.5. Market Value Forecast, by Distribution Channel, 2017-2031

            10.5.1. Hospital Pharmacies

            10.5.2. Retail Pharmacies

            10.5.3. Online Pharmacies

        10.6. Market Value Forecast, by Country, 2017-2031

            10.6.1. U.S.

            10.6.2. Canada

        10.7. Market Attractiveness Analysis

            10.7.1. By Therapeutics

            10.7.2. By Indication

            10.7.3. By Distribution Channel

            10.7.4. By Country

    11. Europe Gynecology Drugs Market Analysis and Forecast

        11.1. Introduction

        11.2. Key Findings

        11.3. Market Value Forecast, by Therapeutics, 2017-2031

            11.3.1. Hormonal Therapy

                11.3.1.1. Estrogen Therapy

                11.3.1.2. Progestin Therapy

                11.3.1.3. Combination Therapy

                11.3.1.4. Thyroid Replacement Therapy

                11.3.1.5. Parathyroid Hormone Therapy

                11.3.1.6. Others

            11.3.2. Non-hormonal Therapy

                11.3.2.1. Anti-Infective Agents

                11.3.2.2. Anti-neoplastic Agents

                11.3.2.3. Anti-inflammatory Agents

                11.3.2.4. Others

        11.4. Market Value Forecast, by Indication, 2017-2031

            11.4.1. Gynecological Cancers

            11.4.2. Endometriosis

            11.4.3. Female Infertility

            11.4.4. Menopausal Disorder

            11.4.5. Gynecology Infections

            11.4.6. Polycystic Ovary Syndrome

            11.4.7. Contraception (Birth Control)

            11.4.8. Others

        11.5. Market Value Forecast, by Distribution Channel, 2017-2031

            11.5.1. Hospital Pharmacies

            11.5.2. Retail Pharmacies

            11.5.3. Online Pharmacies

        11.6. Market Value Forecast, by Country/Sub-region, 2017-2031

            11.6.1. Germany

            11.6.2. U.K.

            11.6.3. France

            11.6.4. Italy

            11.6.5. Spain

            11.6.6. Rest of Europe

        11.7. Market Attractiveness Analysis

            11.7.1. By Therapeutics

            11.7.2. By Indication

            11.7.3. By Distribution Channel

            11.7.4. By Country/Sub-region

    12. Asia Pacific Gynecology Drugs Market Analysis and Forecast

        12.1. Introduction

        12.2. Key Findings

        12.3. Market Value Forecast, by Therapeutics, 2017-2031

            12.3.1. Hormonal Therapy

                12.3.1.1. Estrogen Therapy

                12.3.1.2. Progestin Therapy

                12.3.1.3. Combination Therapy

                12.3.1.4. Thyroid Replacement Therapy

                12.3.1.5. Parathyroid Hormone Therapy

                12.3.1.6. Others

            12.3.2. Non-hormonal Therapy

                12.3.2.1. Anti-Infective Agents

                12.3.2.2. Anti-neoplastic Agents

                12.3.2.3. Anti-inflammatory Agents

                12.3.2.4. Others

        12.4. Market Value Forecast, by Indication, 2017-2031

            12.4.1. Gynecological Cancers

            12.4.2. Endometriosis

            12.4.3. Female Infertility

            12.4.4. Menopausal Disorder

            12.4.5. Gynecology Infections

            12.4.6. Polycystic Ovary Syndrome

            12.4.7. Contraception (Birth Control)

            12.4.8. Others

        12.5. Market Value Forecast, by Distribution Channel, 2017-2031

            12.5.1. Hospital Pharmacies

            12.5.2. Retail Pharmacies

            12.5.3. Online Pharmacies

        12.6. Market Value Forecast, by Country/Sub-region, 2017-2031

            12.6.1. China

            12.6.2. Japan

            12.6.3. India

            12.6.4. Australia & New Zealand

            12.6.5. Rest of Asia Pacific

        12.7. Market Attractiveness Analysis

            12.7.1. By Therapeutics

            12.7.2. By Indication

            12.7.3. By Distribution Channel

            12.7.4. By Country/Sub-region

    13. Latin America Gynecology Drugs Market Analysis and Forecast

        13.1. Introduction

        13.2. Key Findings

        13.3. Market Value Forecast, by Therapeutics, 2017-2031

            13.3.1. Hormonal Therapy

                13.3.1.1. Estrogen Therapy

                13.3.1.2. Progestin Therapy

                13.3.1.3. Combination Therapy

                13.3.1.4. Thyroid Replacement Therapy

                13.3.1.5. Parathyroid Hormone Therapy

                13.3.1.6. Others

            13.3.2. Non-hormonal Therapy

                13.3.2.1. Anti-Infective Agents

                13.3.2.2. Anti-neoplastic Agents

                13.3.2.3. Anti-inflammatory Agents

                13.3.2.4. Others

        13.4. Market Value Forecast, by Indication, 2017-2031

            13.4.1. Gynecological Cancers

            13.4.2. Endometriosis

            13.4.3. Female Infertility

            13.4.4. Menopausal Disorder

            13.4.5. Gynecology Infections

            13.4.6. Polycystic Ovary Syndrome

            13.4.7. Contraception (Birth Control)

            13.4.8. Others

        13.5. Market Value Forecast, by Distribution Channel, 2017-2031

            13.5.1. Hospital Pharmacies

            13.5.2. Retail Pharmacies

            13.5.3. Online Pharmacies

        13.6. Market Value Forecast, by Country/Sub-region, 2017-2031

            13.6.1. Brazil

            13.6.2. Mexico

            13.6.3. Rest of Latin America

        13.7. Market Attractiveness Analysis

            13.7.1. By Therapeutics

            13.7.2. By Indication

            13.7.3. By Distribution Channel

            13.7.4. By Country/Sub-region

    14. Middle East & Africa Gynecology Drugs Market Analysis and Forecast

        14.1. Introduction

        14.2. Key Findings

        14.3. Market Value Forecast, by Therapeutics, 2017-2031

            14.3.1. Hormonal Therapy

                14.3.1.1. Estrogen Therapy

                14.3.1.2. Progestin Therapy

                14.3.1.3. Combination Therapy

                14.3.1.4. Thyroid Replacement Therapy

                14.3.1.5. Parathyroid Hormone Therapy

                14.3.1.6. Others

            14.3.2. Non-hormonal Therapy

                14.3.2.1. Anti-Infective Agents

                14.3.2.2. Anti-neoplastic Agents

                14.3.2.3. Anti-inflammatory Agents

                14.3.2.4. Others

        14.4. Market Value Forecast, by Indication, 2017-2031

            14.4.1. Gynecological Cancers

            14.4.2. Endometriosis

            14.4.3. Female Infertility

            14.4.4. Menopausal Disorder

            14.4.5. Gynecology Infections

            14.4.6. Polycystic Ovary Syndrome

            14.4.7. Contraception (Birth Control)

            14.4.8. Others

        14.5. Market Value Forecast, by Distribution Channel, 2017-2031

            14.5.1. Hospital Pharmacies

            14.5.2. Retail Pharmacies

            14.5.3. Online Pharmacies

        14.6. Market Value Forecast, by Country/Sub-region, 2017-2031

            14.6.1. GCC Countries

            14.6.2. South Africa

            14.6.3. Rest of Middle East & Africa

        14.7. Market Attractiveness Analysis

            14.7.1. By Therapeutics

            14.7.2. By Indication

            14.7.3. By Distribution Channel

            14.7.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)

        15.2. Market Share Analysis, by Company (2022)

        15.3. Company Profiles

            15.3.1. Allergan plc

                15.3.1.1. Company Overview

                15.3.1.2. Product Portfolio

                15.3.1.3. SWOT Analysis

                15.3.1.4. Financial Overview

                15.3.1.5. Strategic Overview

            15.3.2. Amgen Inc.

                15.3.2.1. Company Overview

                15.3.2.2. Product Portfolio

                15.3.2.3. SWOT Analysis

                15.3.2.4. Financial Overview

                15.3.2.5. Strategic Overview

            15.3.3. Bayer AG

                15.3.3.1. Company Overview

                15.3.3.2. Product Portfolio

                15.3.3.3. SWOT Analysis

                15.3.3.4. Financial Overview

                15.3.3.5. Strategic Overview

            15.3.4. Merck & Co., Inc.

                15.3.4.1. Company Overview

                15.3.4.2. Product Portfolio

                15.3.4.3. SWOT Analysis

                15.3.4.4. Financial Overview

                15.3.4.5. Strategic Overview

            15.3.5. Pfizer Inc.

                15.3.5.1. Company Overview

                15.3.5.2. Product Portfolio

                15.3.5.3. SWOT Analysis

                15.3.5.4. Financial Overview

                15.3.5.5. Strategic Overview

            15.3.6. Eli Lilly Company

                15.3.6.1. Company Overview

                15.3.6.2. Product Portfolio

                15.3.6.3. SWOT Analysis

                15.3.6.4. Financial Overview

                15.3.6.5. Strategic Overview

            15.3.7. F. Hoffmann-La Roche Ltd.

                15.3.7.1. Company Overview

                15.3.7.2. Product Portfolio

                15.3.7.3. SWOT Analysis

                15.3.7.4. Financial Overview

                15.3.7.5. Strategic Overview

            15.3.8. AstraZeneca

                15.3.8.1. Company Overview

                15.3.8.2. Product Portfolio

                15.3.8.3. SWOT Analysis

                15.3.8.4. Financial Overview

                15.3.8.5. Strategic Overview

    List of Tables

    Table 01: Global Gynecology Drugs Market Size (US$ Mn) Forecast, by Therapeutics, 2017-2031

    Table 02: Global Gynecology Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031

    Table 03: Global Gynecology Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 04: Global Gynecology Drugs Market Size (US$ Mn) Forecast, by Region, 2017-2031

    Table 05: North America Gynecology Drugs Market Size (US$ Mn) Forecast, by Country, 2017-2031

    Table 06: North America Gynecology Drugs Market Size (US$ Mn) Forecast, by Therapeutics, 2017-2031

    Table 07: North America Gynecology Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031

    Table 08: North America Gynecology Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 09: Europe Gynecology Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 10: Europe Gynecology Drugs Market Size (US$ Mn) Forecast, by Therapeutics, 2017-2031

    Table 11: Europe Gynecology Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031

    Table 12: Europe Gynecology Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 13: Asia Pacific Gynecology Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 14: Asia Pacific Gynecology Drugs Market Size (US$ Mn) Forecast, by Therapeutics, 2017-2031

    Table 15: Asia Pacific Gynecology Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031

    Table 16: Asia Pacific Gynecology Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 17: Latin America Gynecology Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 18: Latin America Gynecology Drugs Market Size (US$ Mn) Forecast, by Therapeutics, 2017-2031

    Table 19: Latin America Gynecology Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031

    Table 20: Latin America Gynecology Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 21: Middle East & Africa Gynecology Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 22: Middle East & Africa Gynecology Drugs Market Size (US$ Mn) Forecast, by Therapeutics, 2017-2031

    Table 23: Middle East & Africa Gynecology Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031

    Table 24: Middle East & Africa Gynecology Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    List of Figures

    Figure 01: Global Gynecology Drugs Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031

    Figure 02: Global Gynecology Drugs Market Revenue (US$ Mn), by Therapeutics, 2022

    Figure 03: Global Gynecology Drugs Market Value Share, by Therapeutics, 2022

    Figure 04: Global Gynecology Drugs Market Revenue (US$ Mn), by Indication, 2022

    Figure 05: Global Gynecology Drugs Market Value Share, by Indication, 2022

    Figure 06: Global Gynecology Drugs Market Revenue (US$ Mn), by Distribution Channel, 2022

    Figure 07: Global Gynecology Drugs Market Value Share, by Distribution Channel, 2022

    Figure 08: Global Gynecology Drugs Market Value Share, by Region, 2022

    Figure 09: Global Gynecology Drugs Market Value (US$ Mn) Forecast, 2023-2031

    Figure 10: Global Gynecology Drugs Market Value Share Analysis, by Therapeutics, 2022 and 2031

    Figure 11: Global Gynecology Drugs Market Attractiveness Analysis, by Therapeutics, 2023-2031

    Figure 12: Global Gynecology Drugs Market Value Share Analysis, by Indication, 2022 and 2031

    Figure 13: Global Gynecology Drugs Market Attractiveness Analysis, by Indication, 2023-2031

    Figure 14: Global Gynecology Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 15: Global Gynecology Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 16: Global Gynecology Drugs Market Value Share Analysis, by Region, 2022 and 2031

    Figure 17: Global Gynecology Drugs Market Attractiveness Analysis, by Region, 2023-2031

    Figure 18: North America Gynecology Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031

    Figure 19: North America Gynecology Drugs Market Attractiveness Analysis, by Country, 2023-2031

    Figure 20: North America Gynecology Drugs Market Value Share Analysis, by Country, 2022 and 2031

    Figure 21: North America Gynecology Drugs Market Value Share Analysis, by Therapeutics, 2022 and 2031

    Figure 22: North America Gynecology Drugs Market Value Share Analysis, by Indication, 2022 and 2031

    Figure 23: North America Gynecology Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 24: North America Gynecology Drugs Market Attractiveness Analysis, by Therapeutics, 2023-2031

    Figure 25: North America Gynecology Drugs Market Attractiveness Analysis, by Indication, 2023-2031

    Figure 26: North America Gynecology Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 27: Europe Gynecology Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031

    Figure 28: Europe Gynecology Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 29: Europe Gynecology Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 30: Europe Gynecology Drugs Market Value Share Analysis, by Therapeutics, 2022 and 2031

    Figure 31: Europe Gynecology Drugs Market Value Share Analysis, by Indication, 2022 and 2031

    Figure 32: Europe Gynecology Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 33: Europe Gynecology Drugs Market Attractiveness Analysis, by Therapeutics, 2023-2031

    Figure 34: Europe Gynecology Drugs Market Attractiveness Analysis, by Indication, 2023-2031

    Figure 35: Europe Gynecology Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 36: Asia Pacific Gynecology Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031

    Figure 37: Asia Pacific Gynecology Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 38: Asia Pacific Gynecology Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 39: Asia Pacific Gynecology Drugs Market Value Share Analysis, by Therapeutics, 2022 and 2031

    Figure 40: Asia Pacific Gynecology Drugs Market Value Share Analysis, by Indication, 2022 and 2031

    Figure 41: Asia Pacific Gynecology Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 42: Asia Pacific Gynecology Drugs Market Attractiveness Analysis, by Therapeutics, 2023-2031

    Figure 43: Asia Pacific Gynecology Drugs Market Attractiveness Analysis, by Indication, 2023-2031

    Figure 44: Asia Pacific Gynecology Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 45: Latin America Gynecology Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031

    Figure 46: Latin America Gynecology Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 47: Latin America Gynecology Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 48: Latin America Gynecology Drugs Market Value Share Analysis, by Therapeutics, 2022 and 2031

    Figure 49: Latin America Gynecology Drugs Market Value Share Analysis, by Indication, 2022 and 2031

    Figure 50: Latin America Gynecology Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 51: Latin America Gynecology Drugs Market Attractiveness Analysis, by Therapeutics, 2023-2031

    Figure 52: Latin America Gynecology Drugs Market Attractiveness Analysis, by Indication, 2023-2031

    Figure 53: Latin America Gynecology Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 54: Middle East & Africa Gynecology Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031

    Figure 55: Middle East & Africa Gynecology Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 56: Middle East & Africa Gynecology Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 57: Middle East & Africa Gynecology Drugs Market Value Share Analysis, by Therapeutics, 2022 and 2031

    Figure 58: Middle East & Africa Gynecology Drugs Market Value Share Analysis, by Indication, 2022 and 2031

    Figure 59: Middle East & Africa Gynecology Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 60: Middle East & Africa Gynecology Drugs Market Attractiveness Analysis, by Therapeutics, 2023-2031

    Figure 61: Middle East & Africa Gynecology Drugs Market Attractiveness Analysis, by Indication, 2023-2031

    Figure 62: Middle East & Africa Gynecology Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Copyright © Transparency Market Research, Inc. All Rights reserved